Rationale: Although Nox5 (Nox2 homolog) has been identified in the vasculature, its regulation and functional significance remain unclear. Objectives: We sought to test whether vasoactive agents regulate Nox5 through Ca 2؉ /calmodulin-dependent processes and whether Ca 2؉ -sensitive Nox5, associated with Rac-1, generates superoxide (O 2 ⅐؊ ) and activates growth and inflammatory responses via mitogen-activated protein kinases in human endothelial cells (ECs). Methods and Results: Cultured ECs, exposed to angiotensin II (Ang II) and endothelin (ET)-1 in the absence and presence of diltiazem (Ca 2؉ channel blocker), calmidazolium (calmodulin inhibitor), and EHT1864 (Rac-1 inhibitor), were studied. Nox5 was downregulated with small interfering RNA. Ang II and ET-1 increased Nox5 expression (mRNA and protein). Effects were inhibited by actinomycin D and cycloheximide and blunted by diltiazem, calmidazolium and low extracellular Ca 2؉ ([Ca 2؉ ] e ). Ang II and ET-1 activated NADPH oxidase, an effect blocked by low [Ca 2؉ ] e , but not by EHT1864. Nox5 knockdown abrogated
R eactive oxygen species (ROS) play a pivotal role as signaling molecules in the regulation of vascular function. Under physiological conditions, ROS modulate cell growth and vasodilation, whereas in pathological conditions, they have been implicated in vascular cell proliferation, contraction, migration, and inflammation and, as such, may be important in vascular diseases. [1] [2] [3] Among the many enzy-matic sources of vascular ROS, the nonphagocytic Nox family of NADPH oxidases are particularly important. 4 -6 The Nox family, based on homologs of the prototype Nox2 (gp91phox), comprises 7 members, Nox1 through Nox7. 7, 8 Vascular cells possess multiple Noxs including Nox1, Nox2, Nox4, 9 -12 and the recently identified Nox5. 7, [13] [14] [15] Common to all vascular Noxs is their ability to generate ROS.
However, the specific species generated, their intracellular distribution, their requirement for interaction with other NADPH oxidase subunits (p22phox, p47phox, p67phox, and p40phox) and the small G protein Rac-1, and their mode of regulation differ. Whereas Nox1 and Nox2 (which localize mainly in the plasma membrane) generate O 2 ⅐Ϫ , Nox4 (which localizes in focal adhesions and endoplasmic reticulum) seems to produce primarily H 2 O 2 . 16 -18 Vascular Noxs are expressed in a cell-specific manner, with endothelial cells expressing mainly Nox2 and Nox4; vascular smooth muscle cells, Nox1, Nox2, and Nox4; and adventitial fibroblasts, Nox2 and Nox4. 19 -21 Regulation of vascular Noxs, through de novo protein synthesis of Nox homologs 22, 23 and phosphorylation of NADPH oxidase regulatory subunits, 24, 25 is multifactorial, involving physical factors (stretch, pressure), chemical factors (pH, O 2 ), and vasoactive agents (angiotensin II [Ang II], endothelin [ET]-1, aldosterone and growth factors). 26, 27 Recent evidence indicates that vascular cells also possess Nox5 of which four splice variants Nox5␣, Nox5␤, Nox5␥, and Nox5␦ have been identified. 15, 28 The Nox5 gene is present in humans, but not in rodents. Unlike other vascular Noxs, Nox5 possesses an amino-terminal calmodulin-like domain with four binding sites for Ca 2ϩ (EF hands) and does not require p22phox or other subunits for its activation. 13, 14, 29 Whether Nox5 regulation involves the small G protein Rac-1, important for other Noxs, is unclear. Binding of Ca 2ϩ to Nox5 induces a conformational change leading to enhanced ROS generation. 29 The functional significance of vascular Nox5 is unknown, although it has been implicated in endothelial cell proliferation and angiogenesis, 15 in plateletderived growth factor-induced proliferation of vascular smooth muscle cells 30 and in oxidative damage in atherosclerosis. 31 Vascular Nox5 is activated by thrombin, plateletderived growth factor, and ionomycin through protein kinase C and cAMP response element-binding protein (CREB). 15, 28, 30, 32 However, it is unknown whether Ang II and ET-1, important vasoactive agonists that regulate vascular contraction, dilation, growth and fibrosis, influence Nox5. Considering that these agonists signal through increased [Ca 2ϩ ] i , as we previously demonstrated, 33, 34 we questioned whether Ang II and ET-1 regulate Nox5 through Ca 2ϩ -and calmodulin-dependent mechanisms and whether Rac-1 plays a role in its activation. In addition, we sought to evaluate whether Nox5-based NADPH oxidase is functionally important in redox signaling involved in growth and inflammatory responses by Ang II and ET-1 in human endothelial cells.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Cell Culture
Human microvascular endothelial cells (ECs) (Human Microvascular Endothelial Cells adult dermis [HMVECad], #C-011-5C, Cascade Biologics, low passage) were studied. Cells were stimulated with Ang II or ET-1 (0.1 mol/L) for 2 to 24 hours. In some studies, cells were exposed to the following inhibitors 30 minutes before stimulation: diltiazem (Ca 2ϩ channel blocker, 0.1 mol/L), calmidazolium (selective calmodulin inhibitor, 0.1 mol/L), EHT1864 (Rac-1 inhibitor, 1 mol/L), PD98059 (MEK1/2 inhibitor, 1 mol/L), actinomycin D (transcription inhibitor, 10 mol/L), and cycloheximide (protein synthesis inhibitor, 1 mol/L). Cells were also exposed to reduced Ca 2ϩ media containing 50% less Ca 2ϩ than the normal media.
Immunofluorescence Microscopy
Cells were incubated with primary antibody overnight at 4°C (anti-Nox 5 from D. Lambeth and K. Heinz Kraus, 1:500), anti-Nox 2 (from M. Quinn, 1:500), anti-Nox 4 (Santa Cruz Biotechnology, 1:500) and DAPI (Molecular Probes, 1:2000) . Proteins were detected with anti-rabbit secondary antibody (Alexa fluor 488, Molecular Probes, 1:1000). Immunofluorescence images were acquired and analyzed (Stallion High Speed Digital Microscopy Workstation, Slidebook, Zeiss).
Nox5 mRNA Detection
Quantitative real-time PCR (Applied Biosystems) was used to analyze mRNA expression of Nox5. Expression of Nox5 was interpolated from a standard curve (constructed from an independent sample of pooled EC cDNA) and expressed relative to 18S.
Western Blotting
Western blotting was used to examine expression of Nox1, Nox2, Nox4, Nox5, L-type Ca 2ϩ channel, VCAM-1, and proliferating-cell nuclear antigen (PCNA), GAPDH, ␤-actin, and activation (phosphorylation) of extracellular signal-regulated kinase (ERK)1/2, p38 mitogen-activated protein kinase (MAPK), stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK), and CREB. In some experiments, positive Nox5 controls (Nox 5-overexpressing HEK 293 cells, 15, 29 ovarian tumor cell lines (gift from B. Vanderhyden, Ottawa Hospital Research Institute, University of Ottawa) and negative controls (rat vascular smooth muscle cells) were included.
Measurement of Intracellular Free Ca 2؉ Concentration ([Ca 2؉ ] i )
Endothelial cell [Ca 2ϩ ] i was measured using the fluorescent probe fura-2AM (Molecular Probes) as we previously described. 35 [Ca 2ϩ ] i responses were measured in cells exposed to Ang II, ET-1 and the L-type Ca 2ϩ channel agonist 1 to 4-dihydro-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl) phenyl] pyridine-3-carboxylic acid (Bay K8644, 0.1 mol/L) in the presence of extracellular Ca 2ϩ . In some studies, 
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Measurement of NAD(P)H Oxidase Activity
The lucigenin-derived chemiluminescence assay was used to determine NAD(P)H oxidase activity in total EC homogenates as previously described. 35 Activity was expressed as arbitrary units/mg protein.
Nox 5 siRNA Transfection Studies
To examine the role of Nox5 in ROS production and signaling, ECs were transiently transfected with small interfering (si)RNA against human Nox5 (Santa Cruz Biotechnology). Gene silencing was monitored by Nox5 protein expression. After 48 hours of siRNA transfection, cells were stimulated with Ang II or ET-1, and production of ROS, phosphorylation of ERK1/2, p38 MAPK and SAPK/JNK and expression of PCNA and VCAM-1 were measured.
Immunoprecipitation
To evaluate whether Nox5 associates with calmodulin, we immunoprecipitated Nox5 (anti-Nox5 antibody from Santa Cruz Biotechnol-ogy) and probed for calmodulin in basal and stimulated conditions. See the Online Data Supplement.
Data Analysis
Effects of Ang II and ET-1 were determined relative to vehicle, with the control normalized to 100%. Results are presented as meansϮSEM and compared by ANOVA or by the Student t test when appropriate. Values of PϽ0.05 were considered to be significant.
Results
Subcellular Distribution of Nox5
Cellular localization of Nox2, Nox4 and Nox5 was assessed by immunofluorescence. In ECs Nox 5 was localized primarily in the perinuclear area (Online Figure I, A and B) . In contrast, Nox2 and Nox4 were distributed in both the cytosol and the plasma membrane (Online Figure I, C and D). Using the same antibody (Lambeth antibody) as that for the immunofluorescence studies, we show by Western blotting that Nox5 is indeed expressed (75 kDa) in human endothelial cells, as well as in Nox5-overexpressing HEK cells, ovarian tumor cell lines, and human vascular smooth muscle cells, but not in native HEK cells.
Effects of Ang II and ET-1 on Nox 5 Expression in Human Endothelial Cells: Role of Ca 2؉ /Calmodulin
Exposure of ECs to Ang II and ET-1 increased Nox5 expression at both the gene and protein levels, as assessed by real-time PCR and Western blotting ( Figure 1A To assess the role of Ca 2ϩ /calmodulin in Ang II-and ET-1-induced regulation of Nox5, cells were exposed to diltiazem (a L-type Ca 2ϩ channel blocker) or calmidazolium (a calmodulin inhibitor) for 30 minutes before agonist stimulation (24 hours). The presence of L-type Ca 2ϩ channels in ECs was confirmed by Western blotting. As shown in Online Figure IX (A and B) , human ECs possess L-type Ca 2ϩ channels, which are regulated by Ang II and ET-1. Ang II-induced Nox5 expression was decreased in the presence of diltiazem, calmidazolium and reduced Ca 2ϩ medium ( Figure  2A and 2B). Manipulating cellular Ca 2ϩ levels by diltiazem or reduced Ca 2ϩ medium also decreased ET-1-induced Nox5 expression ( Figure 2C ), whereas calmidazolium treatment only partially inhibited ET-1-induced effects ( Figure 2D ). Cells were exposed to diltiazem (L-type Ca 2ϩ channel blocker) or calmidazolium (calmodulin inhibitor) for 30 minutes before agonist stimulation (24 hours). In some experiments, cells were grown in reduced Ca 2ϩ culture media containing 50% of normal Ca 2ϩ levels (Ca 2ϩ 50%). Top, Representative immunoblots. Results were normalized to GAPDH. Control (indicated as C) was taken as 100%, and data are presented as the percentage changes relative to control conditions. Data are meansϮSEM from 5 experiments. *PϽ0.05 vs control.
Ang II-and ET-1-Induced ROS Production Is Ca 2؉ -Dependent
To determine whether Ang II and ET-1 influence NADPH oxidase activation through Ca 2ϩ -dependent processes, oxidase activity was measured by enhanced lucigenin chemiluminescence in cells that were exposed to reduced [Ca 2ϩ ] e . As shown in Figure 3A and 3B, Ang II and ET-1 induced a significant increase in NADPH oxidase activation. This effect was significantly blunted when cells were grown in low Ca 2ϩ -containing medium (Figure 3C and 3D) and in the presence of calmidazolium ( Figure 4A and 4B) . To confirm an association between Nox5 and calmodulin, we immuno- precipitated Nox5 and probed for calmodulin. As shown in Figure 4C , even in basal conditions, calmodulin associates with Nox5, an effect that is enhanced by Ang II and ET-1.
siRNA Knockdown of Nox5 Decreases ROS Production in Human ECs
Because Nox5 is a Ca 2ϩ -dependent Nox homolog and because we found that agonist stimulated NADPH oxidase is Ca 2ϩ -sensitive, we questioned whether Nox5-based NADPH oxidase contributes to ROS production in ECs. Using siRNA Nox5 was downregulated in ECs. Significant reduction in expression of Nox5, but not Nox4, was evident after 48 and 72 hours of incubation with siRNA. Because the knockdown of Nox5 was optimal at 48 hours (PϽ0.05), this time point was used for further experiments ( Figure 5A ).
Knockdown of Nox5 by RNA interference abrogated ROS generation induced by Ang II and ET-1 ( Figure 5B and 5C ). EHT1864, a Rac1 inhibitor, did not interfere with Ang IIand ET-1-induced NADPH oxidase activation ( Figure 5D ), but decreased Ang II-and ET-1-stimulated Rac-1 translocation, as evidenced by decreased membrane expression of Rac-1 (Online Figure XI) .
siRNA Knockdown of Nox5 Attenuates Ang IIand ET-1-Induced Effects on ERK1/2, but not p38 MAPK or SAPK/JNK, Phosphorylation and Differentially Influences VCAM-1 and PCNA Expression
To assess the functional significance of Nox5-based NADPH oxidase in ECs, we evaluated the effects of Ang II and ET-1 on ERK1/2 phosphorylation and growth and inflammatory responses. As shown in Figure 6A , downregulation of Nox5 is associated with significantly reduced activation of ERK1/2, but had no effect on phosphorylation of p38 MAPK and SAPK/JNK (Online Figure XII, A and B ). Short-term (5minute) exposure to Ang II and ET-1 increased ERK1/2 phosphorylation. In Nox5 siRNA-transfected cells, neither Ang II nor ET-1 increased ERK1/2 activation ( Figure 6A ). Treatment with calmidazolium also blocked Ang II-and ET-1-induced activation of ERK1/2 ( Figure 6B ). Ang II and ET-1 increased expression of VCAM-1 and PCNA, molecular markers of inflammation and cell growth. Downregulation of Nox5 by siRNA ( Figure 7A through 7D) and ERK1/2 inhibition (Online Figure XIII) blunted Ang II-induced, but not ET-1-induced upregulation of VCAM-1 and PCNA.
Discussion
Major findings from our study demonstrate that (1) human ECs possess a functionally active Nox5-based NADPH oxidase that localizes in the perinuclear region; (2) Ang II and ET-1 regulate Nox5 through Ca 2ϩ -and calmodulindependent and Rac-1-independent processes; (3) Nox5, which associates with calmodulin, is involved in ROS generation and ERK1/2, but not p38MAPK or SAPK/JNK, signaling by Ang II and ET-1; and (4) Nox5 is involved in PCNA and VCAM regulation by Ang II but not by ET-1. Our findings elucidate novel mechanisms whereby vasoactive peptides regulate Nox5 in human endothelial cells (Figure 8 ). Such phenomena link Ca 2ϩ /calmodulin to Nox5-mediated ROS production and ERK1/2 signaling, important factors in the regulation of endothelial function by agonists that signal through G protein-coupled receptors, such as Ang II and ET-1. We also highlight the fact that Nox5 is differentially involved in functional responses to Ang II and ET-1. Whereas Nox5 is involved in growth and inflammatory responses induced by Ang II, this is not so for ET-1. Moreover regulation of MAPKs is highly specific, because activation of ERK1/2, but not p38 MAPK or SAPK/JNK, by Ang II and ET-1 involves Nox5-sensitive processes.
Endothelial cells are involved in maintaining normal vascular function and integrity. Under pathological conditions, the phenotype of endothelial cells changes from being vasodilatory, antiinflammatory and antithrombotic to proinflammatory, angiogenic, adhesive and contractile. Critical to these processes is an increased bioavailability of ROS, generated in response to activation of Nox-based NADPH oxidases. 36 Human ECs possess multiple Nox homologs including Nox1, Nox2, Nox4, and Nox5, 9 -15 the functional significance of which still remains elusive. Petry et al demonstrated that in human ECs Nox2 and Nox4 are abundantly expressed and that they contribute equally to ROS production. 37 Nox1 is less prominent than other Noxs in ECs and does not appear to be important in ROS generation, because Nox1 depletion did not alter ROS levels under basal conditions. 9, 38 In human lung endothelial cells, Nox2 and Nox4 play a physiological role in hyperoxia-induced ROS production and migration. 39 Nox5, although extensively expressed in lymphatic cells, prostate and testes, has only recently been identified in ECs. We demonstrate here that Nox5 has a predominantly intracellular distribution in human ECs, mainly in the perinuclear region, whereas Nox2 and Nox4 localize in the plasmalemmal area. Nox5 appears to concentrate in the endoplasmic reticulum, whereas Nox4 has been identified in focal adhesions. [13] [14] [15] The differential distribution of Nox homologs in ECs may relate to functional diversity and possibly to Nox-specific generation of distinctive reactive oxygen species. For example, Nox4 seems to generate mainly H 2 O 2 whereas Nox5 produces O 2 ⅐Ϫ , H 2 O 2 , and NO. 15, 37, 40 Moreover, although Nox2 and Nox4 require other NADPH oxidase subunits, particularly p22phox, for their regulation, Nox5 does not seem to have an obligatory need for these regulatory subunits. [13] [14] [15] Finally, different Nox homologs appear to activate different kinases and signaling pathways. For example in Nox2 overexpressing cells, p38MAPK is phosphorylated in response to Ang II, whereas in Nox4 overexpressing cells, ERK1/2 and JNK are activated. 41, 42 Molecular mechanisms controlling Nox5 have not been fully elucidated, but protein kinase C, c-Abl, CREB and phosphatidylinositol 4,5 -bisphosphate have been implicated. 32, [43] [44] [45] Considering the unique feature of Nox5 in that it possesses a calmodulin-like domain with 4 binding sites for Ca 2ϩ , we questioned whether Ang II and ET-1, which increase [Ca 2ϩ ] i , regulate Nox5 through Ca 2ϩ and calmodulin-dependent processes. Both agonists, important in endothelial function, significantly increased mRNA and protein expression of Nox5, but not Nox1, Nox2 or Nox4, in a time-dependent manner. Nox5 regulation appears to be both at the transcriptional and translational levels, because actinomycin D and cycloheximide prevented agonist-induced increase in Nox5 expression. These Nox5 effects are not Figure 6 . siRNA knockdown of Nox5 decreases ERK1/2 activation. Downregulation of Nox5 and inhibition of calmodulin were associated with significantly reduced activation of ERK1/2. Short-term (5 minutes) exposure to Ang II and ET-1 increased ERK1/2 phosphorylation. In Nox5 siRNA-transfected cells (A) and cells exposed to calmidazolium (B), neither Ang II nor ET-1 increased ERK1/2 activation. Data are meansϮ SEM from 5 experiments. *PϽ0.05 vs control (indicated as C) and nonsilenced (NS) conditions. generalized phenomena, as other vasoactive agonists, such as aldosterone, did not influence expression of Nox5 in our study. We also showed that in human ECs Ang II and ET-1 significantly increased [Ca 2ϩ ] i , in part through L-type Ca 2ϩ channels, and that this phenomenon influences Nox5 regulation. This is based on the findings that: (1) agonist-induced increases in Nox5 expression are reduced when cells are cultured in low Ca 2ϩ -containg medium; (2) the upregulation of Nox5 by Ang II and ET-1 is attenuated in cells pretreated with the L-type Ca 2ϩ channel blocker diltiazem; (3) Ang IIand ET-1-stimulated Nox5 expression is decreased in ECs exposed to the calmodulin inhibitor calmidazolium; and (4) the L-type Ca 2ϩ channel agonist Bay K8644 stimulates Ca 2ϩ influx and increases Nox5 expression. These data indicate that Ang II and ET-1 promote Ca 2ϩ influx through L-type Ca 2ϩ channels, which we show here to be functionally present in human ECs, and that this results in increases in [Ca 2ϩ ] i that modulate Nox5. This process probably also involves calmodulin as evidenced by the findings that calmidazolium attenuated agonist-induced Nox5 responses and that Ang II and ET-1 promote Nox5:calmodulin association.
Although Nox5 activation appears to be independent of the NADPH oxidase subunits p22phox, p47phox, and p67phox, 13, 14, 29 it is unknown whether Rac-1, important in the regulation of other Noxs, is involved in Nox5 regulation. 46 Here, we show that the Rac-1 inhibitor EHT1864 does not influence Nox5-based NADPH oxidase-derived ROS generation in response to Ang II and ET-1, although it inhibited agonist-stimulated Rac1 membrane translocation. These findings suggest that Nox5, at least in human ECs, does not have an obligatory need for Rac-1 for its activation. Our findings are in keeping with recent data demonstrating that whereas Nox1, Nox2, and Nox3 contain Rac-binding sites, Nox5 does not. 47 To elucidate the functional significance of Nox5 we examined ROS generation and MAPK activation by Ang II and ET-1 in human ECs in which Nox5 was knocked down with siRNA. Although Nox5 was not completely knocked down activation of NADPH oxidase was inhibited. Reasons for this are complex but may relate to the fact that perhaps Nox5 downregulation influences other NADPH oxidase subunits that may impact on activity of the oxidase. It is also possible that Nox5 might interact with other Nox isoforms, which in the context of Nox5 downregulation, would inhibit Nox5-associated Nox activity. Such considerations require further examination.
In Nox5 downregulated cells, phosphorylation of ERK1/2, but not p38 MAPK or SAPK/JNK, was significantly reduced, indicating the importance of Nox5 in redox-and ERK1/2 signaling by Ang II and ET-1. Moreover, these processes are Ca 2ϩ -sensitive, because exposure of cells to low Ca 2ϩ attenuated ROS generation and ERK1/2 signaling. Hence, not only does [Ca 2ϩ ] i influence expression of Nox5, but it also regulates enzymatic activity of Nox5-based NADPH oxidase and ROS production. We showed that Ang II and ET-1 at concentrations above 0.01 mol/L increase vascular cell [Ca 2ϩ ] i to levels of Ϸ 1 mol/L, the concentration at which Nox5 is highly sensitive to Ca 2ϩ . On increases in [Ca 2ϩ ] i , Nox5 undergoes a conformational change leading to the activation of NADPH oxidation and electron transport. 13, 14, 28, 29 At lower [Ca 2ϩ ] i , Nox5 is regulated through protein kinase C-dependent processes, which induce phosphorylation of residues 494 and 498 and enhanced enzyme activation. 43, 44 The functional effects of Nox5 are not generalized phenomena and appear to have differential outcomes. Whereas Nox5 appears to be critical in growth and inflammatory responses by Ang II, this may not be so for ET-1. This is supported by the findings that agonist-stimulated expression of PCNA and VCAM-1, molecular markers of growth and inflammation, respectively, was suppressed by Nox5 downregulation and PD98059 only in Ang II-stimulated cells. The point of divergence in the signaling cascade for this differential response is downstream of ROS, because Nox5 is involved in ROS generation by both Ang II and ET-1.
Our findings have pathophysiological significance because Ang II and ET-1 play an important role in endothelial dysfunction and vascular damage and have been implicated in various cardiovascular pathologies associated with oxidative stress, including hypertension, atherosclerosis, and ischemia/ reperfusion injury. Guzik et al recently showed that in coronary arteries from patients with coronary artery disease, Nox5 protein and mRNA levels are increased and Ca 2ϩdependent NADPH-driven production of ROS in vascular membranes is augmented. 31 They also demonstrated that Nox5 was expressed in the endothelium in the early stage lesions and in vascular smooth muscle cells in the advanced coronary lesions, suggesting that Nox5 is an important source of ROS in atherosclerosis. 31 In conclusion, our data demonstrate that human ECs possess functionally active Nox5 that is regulated at the transcriptional and translational levels by Ang II and ET-1 through Ca 2ϩ -and calmodulin-sensitive processes. Unlike other Noxs, Nox5 does not appear to have an obligatory need for Rac-1 for its activation, at least in human ECs. Regulation by Ang II and ET-1 occurs at multiple levels: acutely by activating Nox5-based NADPH oxidase enzymatic activity and chronically by regulating expression of Nox5 mRNA and protein. Moreover, we show that Ang II and ET-1 signal through Nox5 via highly specific ERK1/2-mediated processes. These phenomena link Ca 2ϩ to Nox5-based NADPH oxidase-derived ROS production and ERK1/2 signaling, crucial pathways in the regulation of vascular function by Ang II and ET-1. Such events may be involved in Ca 2ϩ -and redox-sensitive phenomena underlying endothelial function. Dysregulation of these processes, attributable to augmented Ang II and ET-1 signaling, may lead to Ca 2ϩ overload and Nox5-derived oxidative stress which could contribute to endothelial dysfunction and vascular disease. There is a paucity of information on the regulation, signaling, and function of Nox5. Because Nox5 is distinctive in that it possesses Ca 2ϩ -binding sites, we questioned whether this Nox is regulated by Ang II and ET-1, vasoactive agonists that potently increase [Ca 2ϩ ] i . We show that human endothelial cells possess functionally active Nox5 that is regulated at the transcriptional and translational levels through Ca 2ϩ -and calmodulin-sensitive processes and that, unlike other Noxs, Nox5 does not have an obligatory need for Rac-1 for its activation. Regulation by Ang II and ET-1, through Ca 2ϩ , occurs at multiple levels: acutely by activating Nox5-based NADPH oxidase and chronically by regulating Nox5 mRNA and protein expression. Furthermore, Ang II and ET-1 signal through Nox5 via highly regulated ROS-ERK1/ 2-dependent pathways, with Nox5 being particularly important in Ang II-stimulated cell growth and inflammation. Our findings elucidate a novel mechanism linking Ca 2ϩ and Nox5-based NADPH oxidase-derived ROS production and ERK1/2 signaling, critically involved in vascular regulation by Ang II and ET-1. Of pathophysiological significance, dysregulation of these processes, attributable to amplified Ang II and ET-1 signaling, leads to Ca 2ϩ overload and associated Nox5-derived oxidative stress. Such events contribute to oxidative damage, endothelial dysfunction, and vascular injury in cardiovascular disease.
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